Rejuvenated Robben keeps Netherlands dream alive

(Reuters) – Netherlands coach Bert van Marwijk’s biggest gamble was keeping an injured Arjen Robben in his World Cup squad and it paid off handsomely after the winger recovered in time to help steer the Dutch to the final.

Robben suffered a hamstring injury six days before the start of the tournament and did not join the squad that travelled to South Africa on June 5 but stayed home for intensive treatment.

He was able to join his team mates just a week later and was deemed fit enough to make his first appearance of the tournament in their final group match against Cameroon on June 24.

Van Marwijk explained that the prognosis for Robben’s recovery looked so much better the morning after the injury that the coach was willing to risk keeping him in the squad.

His decision had widespread support among all the players.

“With his own style and qualities Arjen has something others don’t have,” striker Robin van Persie said.

Robben’s introduction in the second half against Cameroon proved decisive when he curled a left-foot shot against the post and Klaas-Jan Huntelaar netted the rebound to secure a 2-1 win.

FIRST START

Robben made his first start at the finals in the second round game with Slovakia and needed just 18 minutes to reward Van Marwik’s patience when he cut in from the right flank to put the Dutch ahead with a well-placed shot from 20 meters.

“It was a great experience to be on the pitch again from the first minute and to be decisive for the team, it’s a great feeling,” he said after a 2-1 win put them in the last eight.

Robben did not play his best against Brazil but was still involved in both goals, scored by Wesley Sneijder, and tormented the opposing defence so often that Felipe Melo stamped on him in frustration and was sent off with his side trailing 2-1.

Robben netted his second goal in the semi-final against Uruguay when he headed home a fine cross from Dirk Kuyt to make it 3-1 three minutes after being involved in the attack that resulted in Sneijder putting the Dutch ahead. They won 3-2.

With the artful Robben drawing most attention from opposing defences, the Dutch have been able to focus on the teamwork that has taken them back to Soccer City — where they began against Denmark on June 14 — to face Spain in Sunday’s final.

Robben may have missed the start of the campaign but he has made sure he will have a big role to play at the finish.

(Editing by Ken Ferris)

Rejuvenated Robben keeps Netherlands dream alive

(Reuters) – Netherlands coach Bert van Marwijk’s biggest gamble was keeping an injured Arjen Robben in his World Cup squad and it paid off handsomely after the winger recovered in time to help steer the Dutch to the final.

Robben suffered a hamstring injury six days before the start of the tournament and did not join the squad that traveled to South Africa on June 5 but stayed home for intensive treatment.

He was able to join his team mates just a week later and was deemed fit enough to make his first appearance of the tournament in their final group match against Cameroon on June 24.

Van Marwijk explained that the prognosis for Robben’s recovery looked so much better the morning after the injury that the coach was willing to risk keeping him in the squad.

His decision had widespread support among all the players.

“With his own style and qualities Arjen has something others don’t have,” striker Robin van Persie said.

Robben’s introduction in the second half against Cameroon proved decisive when he curled a left-foot shot against the post and Klaas-Jan Huntelaar netted the rebound to secure a 2-1 win.

FIRST START

Robben made his first start at the finals in the second round game with Slovakia and needed just 18 minutes to reward Van Marwik’s patience when he cut in from the right flank to put the Dutch ahead with a well-placed shot from 20 meters.

“It was a great experience to be on the pitch again from the first minute and to be decisive for the team, it’s a great feeling,” he said after a 2-1 win put them in the last eight.

Robben did not play his best against Brazil but was still involved in both goals, scored by Wesley Sneijder, and tormented the opposing defense so often that Felipe Melo stamped on him in frustration and was sent off with his side trailing 2-1.

Robben netted his second goal in the semi-final against Uruguay when he headed home a fine cross from Dirk Kuyt to make it 3-1 three minutes after being involved in the attack that resulted in Sneijder putting the Dutch ahead. They won 3-2.

With the artful Robben drawing most attention from opposing defenses, the Dutch have been able to focus on the teamwork that has taken them back to Soccer City — where they began against Denmark on June 14 — to face Spain in Sunday’s final.

Robben may have missed the start of the campaign but he has made sure he will have a big role to play at the finish.

(Editing by Ken Ferris)

Injured Ghana goal hero faces race against time

(Reuters) – Ghana goal hero Kevin-Prince Boateng faces a week of intensive therapy in a bid to get fit for the World Cup quarter-final after suffering a hamstring injury.

Sports

Boateng scored a fifth minute goal on Saturday to set his side on the way to a 2-1 win over the United States in their second round match in Rustenburg but later limped off in the second half.

Coach Milovan Rajevac said the Germany-born midfielder would face intensive treatment in a bid to be ready for the match against Uruguay at Soccer City in Johannesburg on Friday.

Boateng was among several Ghana players limping after the exertions of the extra time triumph over the Americans at the Royal Bafokeng Stadium.

“Boateng was injured against Germany already. It is going to be a huge problem to get him ready for the next game,” said Rajevac following the record-equaling performance by Ghana, only the third African country to reach the last eight of the World Cup.

NIGGLING INJURIES

Rajevac said there were also other players with niggling injuries. Dede Ayew will also miss the match through suspension after picking a second caution of the tournament.

“We are going to see how the players react in the next days. For me the priority now will be to try and get them all ready for Friday. There is a lot of work ahead for the medical staff.”

The Serbian-born coach praised the efforts of his players who he said had learnt how to compete.

“We played in the African Nations Cup this year without eight important players and managed to reach the final. The team learnt how to compete. The most important thing at this level is to know how to compete,” he said.

“Each victory counts and this is very dear. Ghana is now among the best eight teams in the world. This is fantastic,” he added, keeping a stoical face at the post-match news conference but then breaking into a broad smile once it was over.

Ghana are the only African side left at the World Cup and for a second successive tournament the only team from the continent to get past the first round.

“I think we can claim to be the best team in Africa now if you consider that, plus the fact we reached the Nations Cup final,” added captain John Mensah.

(Editing by Michael Holden)

Lowering BP to normal levels doesn’t help diabetics

London, Mar 15 (ANI): Lowering blood pressure to normal levels does not reduce the combined risk of fatal or nonfatal cardiovascular disease events in type 2 diabetes patients prone to such events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

Similarly, treating multiple blood lipids with combination drug therapy of a fibrate and a statin did not reduce the combined risk of cardiovascular disease events more than treatment with statin alone.

ACCORD, the study of more than 10,000 participants, is one of the largest studies ever conducted in adults with type 2 diabetes who were at especially high risk of cardiovascular events, such as heart attacks, stroke, or death from cardiovascular disease.

The multicenter clinical trial tested three potential strategies to lower the risk of major cardiovascular events—intensive control of blood sugar, intensive control of blood pressure, and treatment of multiple blood lipids.

The lipids targeted for intensive treatment were high density lipoprotein (HDL) cholesterol and triglycerides, in addition to standard therapy of lowering low density lipoprotein (LDL) cholesterol.

“ACCORD provides important evidence to help guide treatment recommendations for adults with type 2 diabetes who have had a heart attack or stroke or who are otherwise at especially high risk for cardiovascular disease. This information provides guidance to avoid unnecessarily increasing treatment that provides limited benefit and potentially increases the risk of adverse effects,” said Dr. Susan B. Shurin.

For the study, the researchers randomly assigned 4,733 participants with elevated blood pressure to a target systolic blood pressure of either less than 120 mmHg (the intensive group) or to less than 140 mmHg (the standard group).

A variety of FDA-approved blood pressure medications was used to reach blood pressure goals.

After an average follow-up of about five years, the researchers found no significant differences between the intensive group and the standard group in rates of a combined endpoint including nonfatal heart attack, nonfatal stroke, or cardiovascular death.

Lowering blood pressure to below the standard level significantly cut the risk of stroke by about 40 percent.

The intensive blood pressure group had 36 strokes, compared to 62 strokes in the standard group.

However, the researchers warned that participants in the intensive blood pressure group were more likely to have complications such as abnormally low blood pressure or high levels of blood potassium.

“Our results provide no conclusive evidence that targeting a normal systolic blood pressure compared with targeting a systolic blood pressure of less than 140 mmHg lowers the overall risk of major cardiovascular events in high risk adults with type 2 diabetes. However, the study suggests that lower blood pressure levels in patients like those in ACCORD may reduce the risk of stroke. This finding is consistent with other blood pressure trials,” said Dr. William C. Cushman, lead author of the study.

“Our results also showed a higher risk of serious adverse events with more intensive blood pressure control. Diabetic patients should discuss their systolic blood pressure goal with their health care provider and, as with any treatment, weigh the risks and benefits of various treatments to lower blood pressure,” added Cushman.

The results of the ACCORD clinical trials appear online in the New England Journal of Medicine (NEJM). (ANI)